APPLIED THERAPEUTICS INC. - COMMON STOCK

Applied Therapeutics Reports Third Quarter 2024 Financial Results

07 Nov 2024 06:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics Provides Regulatory Update on Govorestat for the Treatment of Classic Galactosemia

18 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Participate in Upcoming Investor Conferences

04 Sep 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Second Quarter 2024 Financial Results

07 Aug 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Added to Russell 3000® Index

01 Jul 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports First Quarter 2024 Financial Results

09 May 2024 06:00:01 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the 2024 RBC Capital Markets Global Healthcare Conference

07 May 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Appoints Dale Hooks as Chief Commercial Officer

15 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Results from Phase 3 ARISE-HF Study in Diabetic Cardiomyopathy at ACC 2024

04 Apr 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Provides FDA Update on PDUFA Target Action Date for Govorestat for the Treatment of Classic Galactosemia

28 Mar 2024 15:30:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Fourth Quarter and Year-end 2023 Financial Results

06 Mar 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces $100 Million Private Placement

28 Feb 2024 07:05:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces FDA Acceptance and Priority Review of New Drug Application for Govorestat for the Treatment of Classic Galactosemia

28 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Positive Results from 12-month Interim Analysis of Govorestat (AT-007) in the Ongoing INSPIRE Phase 3 Trial in Sorbitol Dehydrogenase (SORD) Deficiency

15 Feb 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy

04 Jan 2024 15:05:00 By Nasdaq GlobeNewswire

Applied Therapeutics Announces MAA Validation and NDA Submission of Govorestat (AT-007) for Treatment of Classic Galactosemia

03 Jan 2024 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics Reports Third Quarter 2023 Financial Results

09 Nov 2023 06:30:54 By Nasdaq GlobeNewswire

Applied Therapeutics to Present at the UBS Biopharma Conference 2023

02 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Host Diabetic Cardiomyopathy Expert Forum with Key Opinion Leaders on Tuesday, November 7

01 Nov 2023 06:00:00 By Nasdaq GlobeNewswire

Applied Therapeutics to Present Baseline Data from Phase 3 ARISE-HF Study Evaluating AT-001 at the 2023 EASD Annual Meeting

28 Sep 2023 06:00:00 By Nasdaq GlobeNewswire